An observational study in Multiple Myeloma, sponsored by Fuling Zhou. Enrolling by invitation at 1 site in China. Per ClinicalTrials.gov, last updated 2026-02-13.
Sponsored by Fuling Zhou · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 448 studies in Multiple Myeloma with a site in China — 238 open to participants now, 275 under way, 47 of them phase 3. Multiple Myeloma · China.
Among the 448 studies in Multiple Myeloma with a site in China, this one is the 41st largest by planned enrollment of the 41 observational ones that give a count, is one of 21 that started in 2018, is one of 41 observational ones, reaches primary completion later than 110 of the 274 other live ones, and was the 360th registered.
3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.
Browse Multiple Myeloma studies →238 of the 448 studies in Multiple Myeloma with a site in China are open now. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18+
AstraZeneca · Sites in China, United States, Australia and 15 more countries
Ages 18–130
Mabwell (Shanghai) Bioscience Co., Ltd. · Sites in China
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–80
Chinese PLA General Hospital · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
448 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 216 · Phase 2 130 · Phase 3 71 · Phase 4 16
First in 2008; this study’s year is marked. 21 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 150 across 486 observational studies indexed under Multiple Myeloma.
Median enrollment 40 across the 406 interventional studies, 210 across the 41 observational. Of the 58 that completed or were terminated, 18 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
187 of 448 have an industry lead sponsor. The 10 most frequent:
Fuling Zhou is the lead sponsor of 4 studies on the registry; 4 are open to participants now.
Fuling Zhou has 4 studies filed under Multiple Myeloma — fewer than ten, so there is no comparison to draw.
74 of the studies in Multiple Myeloma with a site in China that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06520176Phase 3The Affiliated People's Hospital of Ningbo UniversityComparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients | 2026-12 |
| NCT05519085Phase 3CelgeneA Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | 2027-01-10 |
| NCT06508983Phase 3Hangzhou Sumgen Biotech Co., Ltd.A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients | 2027-03-31 |
| NCT03319667Phase 3SanofiA Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | 2027-04-05 |
| NCT06895512Phase 3Shanghai Henlius BiotechA Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma | 2027-07 |
Add all 74 to your calendar (.ics) → With an account.
Among the 448 studies in Multiple Myeloma with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study developed an artificial intelligence (AI)-based methodology for the quantitative analysis of single-cell morphological data in multiple myeloma (MM). The approach achieves high-precision AI-driven identification and segmentation of myeloma cells, nuclei, cytoplasm, and nucleoli, overcoming the inherent limitations of subjective traditional morphological analysis.
Furthermore, integrating this morphological quantification with cytogenetic abnormality analysis of myeloma cells provides an efficient predictive tool for identifying high-risk cytogenetic abnormalities.
Leveraging AI-guided selection of genetic testing targets, the research applied a rapid genetic abnormality detection technique utilizing first-drop bone marrow aspirate smears. This methodology achieves orders of magnitude improvements in testing cost, sample preprocessing time and detection sensitivity.
Multiple myeloma (MM) is a malignant plasma cell disorder exhibiting a rising global incidence associated with population aging. The significant intraclonal heterogeneity and complexity of clonal evolution inherent in MM genetics contribute to profound inter-individual heterogeneity. This complicates precise prognostic stratification and disease management, rendering MM largely incurable even in the era of novel therapies. In early-stage MM, primary cytogenetic abnormalities predominantly include odd-numbered chromosome trisomies and immunoglobulin heavy chain gene (IGH) rearrangements, such as t(11;14) and t(4;14). Disease progression and terminal stages are frequently characterized by the acquisition of increasingly complex copy number alterations (CNAs) (e.g., 1q gain/amplification [1q+] and 17p deletion [17p-]) and MYC rearrangements. These secondary events further drive cellular proliferation and tumor growth, collectively contributing to MM's high aggressiveness and therapeutic resistance.
Fluorescence in situ hybridization (FISH), particularly when combined with CD138 immunomagnetic bead sorting for plasma cell enrichment, plays a pivotal role in enhancing the detection rate of cytogenetic abnormalities in MM. However, a comprehensive MM genetic assessment necessitates the selection of multiple FISH probes targeting diverse genetic events, including several associated with high-risk progression. This requirement introduces significant complexity in probe selection. The Mayo Clinic utilizes an initial FISH screening panel for newly diagnosed MM targeting loci on chromosomes 1, 3, 7, 8, 9, 11, 13, 14, 15, and 17. Based on the results from the IGH break-apart probe on chromosome 14 (identifying an IGH break in approximately 50% of NDMM cases), positive cases undergo additional FISH testing for specific translocations: t(4;14), t(6;14), t(14;16), and t(14;20). Nevertheless, implementing such a comprehensive FISH approach is often hindered by the large number of required targets, limited plasma cell yields after bead enrichment/purification, and potential FISH assay failure.
While FISH is crucial for detecting MM cytogenetic abnormalities, current National Comprehensive Cancer Network (NCCN) guidelines highlight up to seven specific high-risk cytogenetic abnormalities associated with progression/relapse in NDMM: 1q21 gain (1q21+), 1p32 deletion (1p32-), del(17p)/monosomy 17 (-17)/TP53 mutation, t(4;14), t(14;16), t(14;20), and MYC rearrangement. The practical clinical application and accuracy of FISH are frequently limited by the extensive number of targets required for a complete assessment and the variability/complexity of standard FISH methodologies. An initial FISH screen must include an IGH break-apart probe. Subsequent testing with specific fusion probes for t(11;14), t(4;14), t(6;14), t(14;16), and t(14;20) is performed only if the IGH break-apart probe is positive.
Previous studies have reported on prognostic significance based on expert morphological classification of myeloma cells into plasmablastic, immature, and mature plasma cell types. However, utilizing myeloma cell morphology to predict specific FISH-detectable cytogenetic abnormalities remains unexplored. Artificial intelligence (AI) has demonstrated growing applications in medical image recognition and classification, including high-precision identification of leukemia, lymphoma, and MM cells. Recent research reported AI's ability to identify four specific acute leukemia molecular subtypes (PML::RARA fusion-positive; NPM1-mutated; CBFB::MYH11 fusion-positive without NPM1 mutation; RUNX1::RUNX1T1 fusion-positive) based on leukemia cell morphology in peripheral blood smears. Yet, analogous studies predicting cytogenetic abnormalities from MM cell morphology are currently lacking.
according to the criteria outlined in the Chinese guidelines for MM diagnosis and management (2024 edition)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
high-precision AI-driven identification and segmentation of myeloma cells, nuclei, cytoplasm, and nucleoli, overcoming the inherent limitations of subjective traditional morphological analysis
Cytogenetic result of multiple myeloma
To predict cytogenetic result of multiple myeloma, using high-precision AI-driven identification and segmentation of myeloma cells, nuclei, cytoplasm, and nucleoli.
Time frame: 2 days
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2018 (actual). Primary completion is estimated for Dec 2026, 100 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fuling Zhou